Improving the use of anticoagulant therapies in acutely ill medical patients

Paul P Dobesh, Katherine W. Phillips, Stuart T. Haines

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose. Assessment of risk for the development of venous thromboembolism (VTE), selection of VTE prophylaxis in medical patients, strategies for improving prescribing practices to prevent VTE, and the impact of pharmacist-managed anti-coagulation services are described; case studies are used to illustrate each topic. Summary. Assessing risk for VTE is more complicated for acutely ill medical patients than for surgical patients. The risk of VTE in medical patients increases with the number of VTE risk factors the patient has. A number of regimens have demonstrated efficacy in reducing the rate of VTE in medically ill patients. Head-to-head studies suggest that enoxaparin 40 mg daily is at least as effective as unfractionated heparin (UFH) 5000 units three times daily for preventing VTE in acute medically ill patients. Because of greater efficacy, enoxaparin may be preferred over UFH in certain patient populations at particularly high risk for VTE. Although the efficacy of VTE prophylaxis is well documented, most patients at risk still do not receive this therapy. A combination of strategies is more effective than a single strategy for modifying prescribing practices to ensure that optimal VTE prophylaxis is provided when indicated. Pharmacist-managed anticoagulation services improve the appropriate use of anticoagulant agents, shorten hospital length of stay, and reduce mortality, drug-related complications, hospital readmissions for bleeding and thrombosis, and costs. Conclusion. Pharmacists can improve clinical and economic outcomes in acutely ill medical patients who are at risk for VTE through the use of various strategies, including anticoagulation management services.

Original languageEnglish (US)
JournalAmerican Journal of Health-System Pharmacy
Volume65
Issue number15 SUPPL. 7
DOIs
StatePublished - Aug 1 2008

Fingerprint

Venous Thromboembolism
Anticoagulants
Therapeutics
Pharmacists
Enoxaparin
Heparin
Length of Stay
Patient Readmission
Thrombosis
Economics
Hemorrhage

Keywords

  • Anticoagulants
  • Drugs
  • Enoxaparin
  • Heparin
  • Hospitals
  • Mortality
  • Pharmacists
  • Pharmacoeconomics
  • Prescribing
  • Rational therapy
  • Toxicity
  • Venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Health Policy

Cite this

Improving the use of anticoagulant therapies in acutely ill medical patients. / Dobesh, Paul P; Phillips, Katherine W.; Haines, Stuart T.

In: American Journal of Health-System Pharmacy, Vol. 65, No. 15 SUPPL. 7, 01.08.2008.

Research output: Contribution to journalArticle

Dobesh, Paul P ; Phillips, Katherine W. ; Haines, Stuart T. / Improving the use of anticoagulant therapies in acutely ill medical patients. In: American Journal of Health-System Pharmacy. 2008 ; Vol. 65, No. 15 SUPPL. 7.
@article{e1eb04e2f65149d9bb8b18ab72db51c7,
title = "Improving the use of anticoagulant therapies in acutely ill medical patients",
abstract = "Purpose. Assessment of risk for the development of venous thromboembolism (VTE), selection of VTE prophylaxis in medical patients, strategies for improving prescribing practices to prevent VTE, and the impact of pharmacist-managed anti-coagulation services are described; case studies are used to illustrate each topic. Summary. Assessing risk for VTE is more complicated for acutely ill medical patients than for surgical patients. The risk of VTE in medical patients increases with the number of VTE risk factors the patient has. A number of regimens have demonstrated efficacy in reducing the rate of VTE in medically ill patients. Head-to-head studies suggest that enoxaparin 40 mg daily is at least as effective as unfractionated heparin (UFH) 5000 units three times daily for preventing VTE in acute medically ill patients. Because of greater efficacy, enoxaparin may be preferred over UFH in certain patient populations at particularly high risk for VTE. Although the efficacy of VTE prophylaxis is well documented, most patients at risk still do not receive this therapy. A combination of strategies is more effective than a single strategy for modifying prescribing practices to ensure that optimal VTE prophylaxis is provided when indicated. Pharmacist-managed anticoagulation services improve the appropriate use of anticoagulant agents, shorten hospital length of stay, and reduce mortality, drug-related complications, hospital readmissions for bleeding and thrombosis, and costs. Conclusion. Pharmacists can improve clinical and economic outcomes in acutely ill medical patients who are at risk for VTE through the use of various strategies, including anticoagulation management services.",
keywords = "Anticoagulants, Drugs, Enoxaparin, Heparin, Hospitals, Mortality, Pharmacists, Pharmacoeconomics, Prescribing, Rational therapy, Toxicity, Venous thromboembolism",
author = "Dobesh, {Paul P} and Phillips, {Katherine W.} and Haines, {Stuart T.}",
year = "2008",
month = "8",
day = "1",
doi = "10.2146/ajhp080240",
language = "English (US)",
volume = "65",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "15 SUPPL. 7",

}

TY - JOUR

T1 - Improving the use of anticoagulant therapies in acutely ill medical patients

AU - Dobesh, Paul P

AU - Phillips, Katherine W.

AU - Haines, Stuart T.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Purpose. Assessment of risk for the development of venous thromboembolism (VTE), selection of VTE prophylaxis in medical patients, strategies for improving prescribing practices to prevent VTE, and the impact of pharmacist-managed anti-coagulation services are described; case studies are used to illustrate each topic. Summary. Assessing risk for VTE is more complicated for acutely ill medical patients than for surgical patients. The risk of VTE in medical patients increases with the number of VTE risk factors the patient has. A number of regimens have demonstrated efficacy in reducing the rate of VTE in medically ill patients. Head-to-head studies suggest that enoxaparin 40 mg daily is at least as effective as unfractionated heparin (UFH) 5000 units three times daily for preventing VTE in acute medically ill patients. Because of greater efficacy, enoxaparin may be preferred over UFH in certain patient populations at particularly high risk for VTE. Although the efficacy of VTE prophylaxis is well documented, most patients at risk still do not receive this therapy. A combination of strategies is more effective than a single strategy for modifying prescribing practices to ensure that optimal VTE prophylaxis is provided when indicated. Pharmacist-managed anticoagulation services improve the appropriate use of anticoagulant agents, shorten hospital length of stay, and reduce mortality, drug-related complications, hospital readmissions for bleeding and thrombosis, and costs. Conclusion. Pharmacists can improve clinical and economic outcomes in acutely ill medical patients who are at risk for VTE through the use of various strategies, including anticoagulation management services.

AB - Purpose. Assessment of risk for the development of venous thromboembolism (VTE), selection of VTE prophylaxis in medical patients, strategies for improving prescribing practices to prevent VTE, and the impact of pharmacist-managed anti-coagulation services are described; case studies are used to illustrate each topic. Summary. Assessing risk for VTE is more complicated for acutely ill medical patients than for surgical patients. The risk of VTE in medical patients increases with the number of VTE risk factors the patient has. A number of regimens have demonstrated efficacy in reducing the rate of VTE in medically ill patients. Head-to-head studies suggest that enoxaparin 40 mg daily is at least as effective as unfractionated heparin (UFH) 5000 units three times daily for preventing VTE in acute medically ill patients. Because of greater efficacy, enoxaparin may be preferred over UFH in certain patient populations at particularly high risk for VTE. Although the efficacy of VTE prophylaxis is well documented, most patients at risk still do not receive this therapy. A combination of strategies is more effective than a single strategy for modifying prescribing practices to ensure that optimal VTE prophylaxis is provided when indicated. Pharmacist-managed anticoagulation services improve the appropriate use of anticoagulant agents, shorten hospital length of stay, and reduce mortality, drug-related complications, hospital readmissions for bleeding and thrombosis, and costs. Conclusion. Pharmacists can improve clinical and economic outcomes in acutely ill medical patients who are at risk for VTE through the use of various strategies, including anticoagulation management services.

KW - Anticoagulants

KW - Drugs

KW - Enoxaparin

KW - Heparin

KW - Hospitals

KW - Mortality

KW - Pharmacists

KW - Pharmacoeconomics

KW - Prescribing

KW - Rational therapy

KW - Toxicity

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=49449098377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449098377&partnerID=8YFLogxK

U2 - 10.2146/ajhp080240

DO - 10.2146/ajhp080240

M3 - Article

VL - 65

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 15 SUPPL. 7

ER -